Skip to content

Positron Emission Tomography Imaging in Transcranial Magnetic Stimulation Intervention for Treatment-resistant Depression

A Prospective Study on the Efficacy and Safety of Transcranial Magnetic Stimulation Intervention for Treatment-Resistant Depression Guided by Positron Emission Tomography Imaging

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104041
Enrollment
Unknown
Registered
2025-06-10
Start date
2025-06-15
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment-resistant Depression

Interventions

TRD group:Maintenance of the original drug regimen combined with PET/MRI-guided transcranial magnetic stimulation therapy

Sponsors

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Signed a written informed consent, willing to participate in the study and be evaluated; 2. This episode met DSM-5 diagnostic criteria for major depression without psychotic symptoms. 3. 18 to 45 years old, gender is not limited; 4. Right-handedness. 5. Han Chinese. 6. Receive two or more adequate doses and courses of antidepressant drugs in different mechanisms that were not effective and had been stable for more than 7. weeks on antidepressant medication prior to enrollment, with non-responsiveness defined as a decrease in HAMD-24 score of = 20; 8. Visual acuity was normal or corrected to normal (>= 1.0), and all had an educational background of junior high school or higher; 9. Ability to complete spatial suppression psychophysical experiment.

Exclusion criteria

Exclusion criteria: 1.Patients with epilepsy, patients with metal objects in their bodies and patients with acute cerebrovascular accidents; 2.Patients with organic mental disorders and mental retardation; 3.Pregnant and lactating women; 4.Presence of serious suicidal behaviour or ideation; 5.Patients with metallic objects in the body or other contraindications to PET/MRI scanning; 6.Benzodiazepines were taken during the experimental period (iin 12 hours).

Design outcomes

Primary

MeasureTime frame
Change in synaptic density after treatment;Change in Suppression Index after treatment;Hamilton Depression Scale (24-items) Total Score Change;

Secondary

MeasureTime frame
Change in the rate of Hamilton Anxiety Scale score;Change in the rate of Beck Scale of Suicidal Ideation score;the Snaith-Hamilton Pleasure Scale;Change in electroencephalogram;Change in the Laukes Emotional Intensity Scale score;Change in the score of Visual Analog Scale (VAS);Change in the score of THINC-it;

Countries

China

Contacts

Public ContactManli Huang

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

huangmanli@zju.edu.cn+86 571 8723 5995

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026